Pepsinogen II in gastritis and Helicobacter pylori infection

Helicobacter ◽  
2022 ◽  
Author(s):  
Francesco Di Mario ◽  
Pellegrino Crafa ◽  
Alberto Barchi ◽  
Lorella Franzoni ◽  
Marilisa Franceschi ◽  
...  
2019 ◽  
Vol 9 (3-4) ◽  
pp. 523-530
Author(s):  
L. B. Drygina ◽  
V. N. Ellenidi ◽  
N. A. Bardysheva ◽  
M. M. Bogoslovskiy

Effective eradication of Helicobacter pylori infection is an important means to reduce the risk of precancerous changes in the gastric mucosa and prevention of gastric cancer. A search for non-invasive diagnostic tools for Helicobacter pylori infection, evaluation of the effectiveness of eradication remains of high importance.The aim of the study was to assess an informative value of detecting pepsinogen I and II as well as serum antibodies to Helicobacter pylori while assessing an efficacy of treated chronic Helicobacter gastritis and identifying preneoplastic changes in the stomach mucosa. There enrolled 113 male patients with chronic gastritis aged 41 to 76, average age- (56.7±0.7) years. Examination of patients was carried out at admission to the clinic, as well as at 2 and 12 months after administering a standard eradication therapy. It was found that Helicobacter pylori infection was detected in 101 (89.4%) patients. Groups of patients with effective eradication therapy were noted. A time-dependent level of antibodies to Helicobacter pylori, as well as measured concentration of pepsinogen I and II after the onset of eradication treatment were determined. Which were analyzed in connection with the results of histology examination of gastric mucosa biopsy specimens and expression of oncoproteins Ki-67, Bcl-2, c-erbB-2, p16 in the gastric mucosa depending on efficacy of eradication therapy. It is shown that effective eradication therapy was characterized by significantly decreased serum level of IgG antibodies to Helicobacter pylori 2 months after the onset of treatment. Moreover, a significantly decreased pepsinogen II and serum IgG antibodies to Helicobacter pylori during eradication therapy were accompanied by a significant decrease in Ki-67 expression in the gastric epithelium. Decreased concentration of pepsinogen II within the first year after Helicobacter pylori eradication therapy was due to a greater decrease in activity of inflammatory changes in the gastric mucosa than to dynamic changes in gastric atrophy and metaplasia. An inverse relation between the serum level of pepsinogen I and atrophy as well as intestinal metaplasia within the gastric mucosa were found.


2021 ◽  
Vol 66 (8) ◽  
pp. 496-501
Author(s):  
L. A. Kornoukhova ◽  
V. L. Emanuel ◽  
N. L. Denisov ◽  
E. L. Nikonov

The purpose of this work was to familiarize doctors with the methods and significance of serological and cultural diagnostics of H. pylori infection on the example of the test for diagnosing the state of the gastric mucosa «Gastropanel». Blood serum tests were performed for 1057 patients and 122 healthy people aged 18-64 years: pepsinogen I (PG I), pepsinogen II (PG II), gastrin-17 (G-17), basal/stimulated), antibodies (IgGHp) to H. pylori (Biohit Oyj, Finland). The medians of the studied group indicators did not exceed the reference intervals. 398 (34%) patients have negative H. pylori status (IgGHp-). 275 (26%) patients with serum PG I≤70 mcg/ml were identified. The ratio of PG I/II≤3 in 84 (8%), 36 of them (43% of the group PG I/II≤3) - IgGHp-.


Medicine ◽  
2021 ◽  
Vol 100 (27) ◽  
pp. e26562
Author(s):  
Hong Yu ◽  
Ying Liu ◽  
Shujing Jiang ◽  
Yunfeng Zhou ◽  
Zheng Guan ◽  
...  

2000 ◽  
Vol 15 (12) ◽  
pp. H2-H2
Author(s):  
IS Mertasudira ◽  
JR Saketi ◽  
A. Djumhana ◽  
J. Widjojo ◽  
SA Abdurachman

2000 ◽  
Vol 15 (12) ◽  
pp. H10-H11
Author(s):  
Budi Purnomo ◽  
Eva J. Soeleman ◽  
Hadjat S. Digdowirogo ◽  
Hartati N. Soehardjo

Sign in / Sign up

Export Citation Format

Share Document